Therapy & Light

Neomedlight, The Fabric of Light for Phototherapy
Section : Neonatal Jaundice


Jaundice, also known as icterus, is a yellow pigmentation of the skin which is caused by high blood bilirubin levels (i.e. hyperbilirubinemia). Bilirubin is a natural yellow pigment produce by the breakdown from the red blood cells. Bilirubin circulates in the blood in the unconjugated form, which is then conjugated in the liver. The conjugation allows the transformation of a water-insoluble molecule in a water-soluble one, from unconjugated bilirubin to conjugated bilirubin, which can then be excreted in the bile.

Hyperbilirubinemia is a frequent disease after birth and occurs in 60 to 70% of term newborns and nearly all of preterm ones. Neonatal hyperbilirubinemia occurs in neonates because there is an imbalance between increased production and decreased elimination of bilirubin related to a temporarily impaired conjugation system of the liver.
The goal of the therapy is to decrease the level of the circulating unconjugated bilirubin or at least keeping it from increasing. Light in the range of approximately 400 to 500 nm with a peak at 460 nm is considered the most effective and is the standard treatment for neonatal Hyperbilirubinemia.
The interaction of blue light with bilirubin causes a photochemical change which transform unconjugated bilirubin into a water-soluble product that can be eliminated without the liver conjugation step.

Level of Bilirubin must be monitored as uncontrolled level of bilirubin can have severe consequences due to the toxicity of the bilirubin to brain (brainstem and basal ganglion); it can cause Kernicterus, or bilirubin encephalopathy, leading to devastating and permanent brain damages.

Section : Crigler Najjar


Crigler-Najjar syndrome is an orphan disease, a rare genetic disorder characterized by elevated levels of bilirubin in the blood (hyperbilirubinemia). This is due to a deficiency in the enzyme called Glucoronyl-transferase (UGT). UGT catalyzes the hepatic conversion of unconjugated bilirubin into conjugated bilirubin which is the soluble form eliminated from the body.

The incidence of Crigler-Najjar syndrome is estimated to be 1 in 750,000-1,000,000 people in the general population. Although, it is difficult to determine the true frequency of Criggler Najjar syndrome because it is misdiagnosed.
There are two forms of this disorder: Crigler-Najjar syndrome type I, characterized by a nearly complete lack of the UGT enzyme activity and severe symptoms; and Crigler-Najjar syndrome type II, characterized by partial UGT enzyme activity and milder symptoms.

The accumulation of unconjugated bilirubin in plasma constitutes a major risk for developing kernicterus, causing permanent and catastrophic brain damages. Current treatment for Criggler-Najjar patients is based on daily phototherapy for 10 to 12 hours. 

Section : Mucositis


Mucositis is a serious side effect of cancer therapy. It is defined as inflammatory and/or ulcerative lesions of the oral and/or gastrointestinal tract. Oral mucositis is a serious and acute side-effect for patients undergoing cancer therapy (chemotherapy and/or radiotherapy).

There are approximatively 500 000 new cases per year. It is more frequent for patients with ENT cancers and leukemia. It may trigger modifications of treatment or therapy discontinuation, thus reducing the chance of recovery from cancer. It can also require enteral or parenteral nutrition with an impact on patient’s quality of life.

Photobiomodulation is recommended since 2014 as a preventive and curative treatment option for oral mucositis by the Multinational Association of Supportive Care in Cancer (MASCC). 

NeoMedLight and H2020
NeoMedLight receives a grant from the European Union to develop its therapy in PhotoBioModulation targeting initially mucositis and dermatitis.
Grant Agreement number: 824755, ONCORED, H2020-SMEInst-2018-2020-1. 

Section : Epithelitis


Epithelitis is a radio-induced dermatitis related to cancer radiotherapy treatments. Some patients undergoing radiation treatment develop this kind of induced skin disease depending on the radiation levels. It affects the patients’ quality of life with high pain that may necessitate modifications of treatment planning or therapy discontinuation. There is no effective treatment. Photobiomodulation still under investigation is a promising treatment.
NeoMedLight and H2020
NeoMedLight receives a grant from the European Union to develop its therapy in PhotoBioModulation targeting initially mucositis and dermatitis.
Grant Agreement number: 824755, ONCORED, H2020-SMEInst-2018-2020-1. 

Section : Sport Medicine


Trauma from sports injuries causes damage to the cells that make up soft tissues. These damaged cells release chemicals that provoke a natural inflammatory response in the body, which result in redness, swelling, warmth and pain in the injured area. Persistent or recurrent inflammation can predispose athletes to early-onset arthritis or degenerative changes in their joints. The application of low level laser therapy (LLLT), Infrared and red light, with a given frequency have been shown to reduce short term inflammation and to accelerate healing and speed up recovery.
Section : Other Applications


Light has many other applications such as regulation of the circadian rhythm, treatment of the tumor cells through photodynamic therapy (PTD)